The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

m-CPP     1-(3-chlorophenyl)piperazine

Synonyms: CHEMBL478, Lopac-C-5554, Tocris-0875, SureCN48931, PIP086, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of NSC49307


Psychiatry related information on NSC49307


High impact information on NSC49307


Chemical compound and disease context of NSC49307


Biological context of NSC49307


Anatomical context of NSC49307


Associations of NSC49307 with other chemical compounds


Gene context of NSC49307


Analytical, diagnostic and therapeutic context of NSC49307


  1. Neuroendocrine responses to m-chlorophenylpiperazine and L-tryptophan in bulimia. Brewerton, T.D., Mueller, E.A., Lesem, M.D., Brandt, H.A., Quearry, B., George, D.T., Murphy, D.L., Jimerson, D.C. Arch. Gen. Psychiatry (1992) [Pubmed]
  2. The serotonergic agent m-chlorophenylpiperazine induces migraine attacks: A controlled study. Leone, M., Attanasio, A., Croci, D., Filippini, G., D'Amico, D., Grazzi, L., Nespolo, A., Bussone, G. Neurology (2000) [Pubmed]
  3. Hypersensitivity to m-chlorophenylpiperazine in a subject with subclinical panic attacks. Kalus, O., Kahn, R.S., Wetzler, S., Asnis, G.M., van Praag, H.M. Biol. Psychiatry (1990) [Pubmed]
  4. Effect of menstrual cycle phase on neuroendocrine and behavioral responses to the serotonin agonist m-chlorophenylpiperazine in women with premenstrual syndrome and controls. Su, T.P., Schmidt, P.J., Danaceau, M., Murphy, D.L., Rubinow, D.R. J. Clin. Endocrinol. Metab. (1997) [Pubmed]
  5. Single doses of the serotonin agonists buspirone and m-chlorophenylpiperazine do not relieve neuropathic pain. Kishore-Kumar, R., Schafer, S.C., Lawlor, B.A., Murphy, D.L., Max, M.B. Pain (1989) [Pubmed]
  6. Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Hollander, E., DeCaria, C.M., Nitescu, A., Gully, R., Suckow, R.F., Cooper, T.B., Gorman, J.M., Klein, D.F., Liebowitz, M.R. Arch. Gen. Psychiatry (1992) [Pubmed]
  7. Hormonal and subjective responses to intravenous m-chlorophenylpiperazine in women with seasonal affective disorder. Levitan, R.D., Kaplan, A.S., Brown, G.M., Vaccarino, F.J., Kennedy, S.H., Levitt, A.J., Joffe, R.T. Arch. Gen. Psychiatry (1998) [Pubmed]
  8. Hyperresponsivity to the serotonin agonist m-chlorophenylpiperazine in Alzheimer's disease. A controlled study. Lawlor, B.A., Sunderland, T., Mellow, A.M., Hill, J.L., Molchan, S.E., Murphy, D.L. Arch. Gen. Psychiatry (1989) [Pubmed]
  9. Serotonergic sensitivity in borderline personality disorder: preliminary findings. Hollander, E., Stein, D.J., DeCaria, C.M., Cohen, L., Saoud, J.B., Skodol, A.E., Kellman, D., Rosnick, L., Oldham, J.M. The American journal of psychiatry. (1994) [Pubmed]
  10. Anger and anxiety responses to m-chlorophenylpiperazine in generalized anxiety disorder. Germine, M., Goddard, A.W., Woods, S.W., Charney, D.S., Heninger, G.R. Biol. Psychiatry (1992) [Pubmed]
  11. Neuroendocrine and behavioral responses to intravenous m-chlorophenylpiperazine (mCPP) in depressed patients and healthy comparison subjects. Anand, A., Charney, D.S., Delgado, P.L., McDougle, C.J., Heninger, G.R., Price, L.H. The American journal of psychiatry. (1994) [Pubmed]
  12. Serotonin function and treatment response to clozapine in schizophrenic patients. Kahn, R.S., Davidson, M., Siever, L., Gabriel, S., Apter, S., Davis, K.L. The American journal of psychiatry. (1993) [Pubmed]
  13. Anxiogenic treatments do not increase fear-potentiated startle in mice. Risbrough, V.B., Geyer, M.A. Biol. Psychiatry (2005) [Pubmed]
  14. Evidence for accelerated desensitisation of 5-HT(2C) receptors following combined treatment with fluoxetine and the 5-HT(1A) receptor antagonist, WAY 100,635, in the rat. Bristow, L.J., O'Connor, D., Watts, R., Duxon, M.S., Hutson, P.H. Neuropharmacology (2000) [Pubmed]
  15. Long-term lithium treatment in rats attenuates m-chlorophenylpiperazine-induced decreases in food intake but not locomotor activity. Aulakh, C.S., Zohar, J., Wozniak, K.M., Hill, J.L., Murphy, D.L. Psychopharmacology (Berl.) (1989) [Pubmed]
  16. Ethopharmacological analysis of the unstable elevated exposed plus maze, a novel model of extreme anxiety: predictive validity and sensitivity to anxiogenic agents. Jones, N., Duxon, M.S., King, S.M. Psychopharmacology (Berl.) (2002) [Pubmed]
  17. 2'-NH2-MPTP in Swiss Webster mice: evidence for long-term (6-month) depletions in cortical and hippocampal serotonin and norepinephrine, differential protection by selective uptake inhibitors or clorgyline and functional changes in central serotonin neurotransmission. Andrews, A.M., Murphy, D.L. J. Pharmacol. Exp. Ther. (1993) [Pubmed]
  18. Hyperphagia Alters Expression of Hypothalamic 5-HT2C and 5-HT1B Receptor Genes and Plasma Des-Acyl Ghrelin Levels in Ay Mice. Nonogaki, K., Nozue, K., Oka, Y. Endocrinology (2006) [Pubmed]
  19. A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses. Barbhaiya, R.H., Buch, A.B., Greene, D.S. Journal of clinical psychopharmacology. (1996) [Pubmed]
  20. Different serotonin receptors mediate blood pressure, heart rate, plasma catecholamine and prolactin responses to m-chlorophenylpiperazine in conscious rats. Bagdy, G., Szemeredi, K., Kanyicska, B., Murphy, D.L. J. Pharmacol. Exp. Ther. (1989) [Pubmed]
  21. Induction of c-Fos expression in specific areas of the fear circuitry in rat forebrain by anxiogenic drugs. Singewald, N., Salchner, P., Sharp, T. Biol. Psychiatry (2003) [Pubmed]
  22. Serotonin neural adaptations to ontogenetic loss of dopamine neurons in rat brain. Kostrzewa, R.M., Reader, T.A., Descarries, L. J. Neurochem. (1998) [Pubmed]
  23. m-Chlorophenylpiperazine excites non-dopaminergic neurons in the rat substantia nigra and ventral tegmental area by activating serotonin-2C receptors. Di Giovanni, G., Di Matteo, V., La Grutta, V., Esposito, E. Neuroscience (2001) [Pubmed]
  24. Plasma levels of m-chlorophenylpiperazine following single oral dose administration of m-chlorophenylpiperazine and trazodone in human volunteers. Lawlor, B.A., Radcliffe, J., Martinez, R., Sunderland, T., Murphy, D.L. Biol. Psychiatry (1997) [Pubmed]
  25. Characterisation of human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors expressed in the human neuroblastoma cell line SH-SY5Y: comparative stimulation by hallucinogenic drugs. Newton, R.A., Phipps, S.L., Flanigan, T.P., Newberry, N.R., Carey, J.E., Kumar, C., McDonald, B., Chen, C., Elliott, J.M. J. Neurochem. (1996) [Pubmed]
  26. Increased 5-HT2C receptor responsiveness occurs on rearing rats in social isolation. Fone, K.C., Shalders, K., Fox, Z.D., Arthur, R., Marsden, C.A. Psychopharmacology (Berl.) (1996) [Pubmed]
  27. Behavioural profiles of putative 5-hydroxytryptamine receptor agonists and antagonists in developing rats. Jackson, H.C., Kitchen, I. Neuropharmacology (1989) [Pubmed]
  28. Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1c) receptors. Conn, P.J., Sanders-Bush, E. J. Pharmacol. Exp. Ther. (1987) [Pubmed]
  29. Serotonin 1B and 2C receptor interactions in the modulation of feeding behaviour in the mouse. Dalton, G.L., Lee, M.D., Kennett, G.A., Dourish, C.T., Clifton, P.G. Psychopharmacology (Berl.) (2006) [Pubmed]
  30. Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Rotzinger, S., Fang, J., Baker, G.B. Drug Metab. Dispos. (1998) [Pubmed]
  31. In vivo electrophysiological examination of 5-HT2 responses in 5-HT2C receptor mutant mice. Rueter, L.E., Tecott, L.H., Blier, P. Naunyn Schmiedebergs Arch. Pharmacol. (2000) [Pubmed]
  32. Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. Porter, R.H., Benwell, K.R., Lamb, H., Malcolm, C.S., Allen, N.H., Revell, D.F., Adams, D.R., Sheardown, M.J. Br. J. Pharmacol. (1999) [Pubmed]
  33. Specificity of ethanollike effects elicited by serotonergic and noradrenergic mechanisms. Krystal, J.H., Webb, E., Cooney, N., Kranzler, H.R., Charney, D.S. Arch. Gen. Psychiatry (1994) [Pubmed]
  34. Functional magnetic resonance imaging and c-Fos mapping in rats following an anorectic dose of m-chlorophenylpiperazine. Stark, J.A., Davies, K.E., Williams, S.R., Luckman, S.M. Neuroimage (2006) [Pubmed]
  35. Serotonergic and noradrenergic dysregulation in alcoholism: m-chlorophenylpiperazine and yohimbine effects in recently detoxified alcoholics and healthy comparison subjects. Krystal, J.H., Webb, E., Cooney, N.L., Kranzler, H.R., Southwick, S.W., Heninger, G.R., Charney, D.S. The American journal of psychiatry. (1996) [Pubmed]
WikiGenes - Universities